Risankizumab vs Ustekinumab in Patients With Crohn Disease: Trial Results
Risankizumab is an interleukin-23 antagonist; ustekinumab is an interleukin-12 and -23 antagonist.
Diagnosis & Disease Information
Herpes Zoster More Likely After COVID-19 Diagnosis in Patients With IBD
Researchers examined the risk for herpes zoster among patients with inflammatory bowel disease following COVID-19 infection.
Aponvie Now Available for Postop Nausea and Vomiting
Aponvie is an injectable emulsion formulation of aprepitant.
GLP-1 Agonists and Endoscopy: GI Specialists Issue Statement
In their statement, the GI specialists noted that they are familiar with safety issues regarding endoscopy in patients with gastroparesis.
Unusual Food Allergy in Children: Signs of Non-IgE-Mediated Reactions
Non-IgE-mediated food allergies are on the rise in children and do not always present with an immediate, anaphylaxis-type reaction
Fecal Microbiota Therapy Rebyota Now Available to Prevent CDI Recurrence
Rebyota is a fecal microbiota suspension for rectal administration.
Generic Version of Pylera an H. Pylori Treatment, Now Available
Each capsule contains 140mg of bismuth subcitrate potassium, 125mg of metronidazole, and 125mg of tetracycline hydrochloride.
Livmarli Approval Expands to Infants as Young as 3 Months With Alagille Syndrome
Previously, the treatment had been approved for patients 1 year of age and older.
Fecal Microbiota Transplantation Effective Option for Pediatric C difficile Infection
Investigators conducted a systematic review and meta-analysis to assess the safety and efficacy of fecal microbiota transplantation for C difficile infection in pediatric patients.
Fiber Supplementation May Decrease Diarrhea Risk for Inpatients on Enteral Nutrition
Researchers evaluated the effects of fiber supplementation on the risk for diarrhea among hospitalized patients receiving enteral nutrition.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...